MMRGlobal Adds Concierge Medicine Specialist Jeremy Fine, M.D. and Pediatrician and New York Times Best-Selling Author Cara
MMRGlobal Adds Concierge Medicine Specialist Jeremy Fine, M.D. and Pediatrician and New York Times Best-Selling Author Cara Natterson, M.D. to Medical Board of Advisors
LOS ANGELES, CA -- (Marketwired) -- 05/17/13 -- MMRGlobal, Inc. (OTCQB: MMRF) ("MMR"), a leading provider of Personal Health Records (PHRs) MyEsafeDepositBox storage solutions and MMRPro document management and imaging systems for healthcare professionals, today announced the addition of two new members to its Medical Board of Advisors. Dr. Cara Natterson, M.D., a Board-Certified Pediatrician, consultant and The New York Times best-selling author on child health and parenting, will assist the Company with its plans to educate parents on the importance of having a Personal Health Record for their children as well as the best ways to offer PHR products and services through pediatricians. Dr. Jeremy Fine, M.D. is a Concierge Medicine Specialist and Board-Certified in Internal Medicine. Based on his personal experience, Dr. Fine will assist the Company educating Concierge Medicine professionals on the value of ensuring that patients maintain an up-to-date PHR. The announcement was made following MMRGlobal CEO Bob Lorsch's appearance on Fox News Radio in a 30-minute interview on "The Vipp Jaswal Report." During the interview, which is available at https://www.facebook.com/#!/MMRGlobal?fref=ts, Lorsch discussed MMR's business and how efforts in Washington to encourage steering a portion of $27 billion in health IT stimulus to emerging growth companies like MMR brought him and his wife Kira to spearhead a humanitarian effort regarding the release of Dr. Shakil Afridi.
Dr. Natterson has written five books, including "Worry Proof," winner of the The Wall Street Journal's Best Health Book of the Year Award, and authored the American Girl book, "The Care & Keeping of You 2." She also updated American Girl's original "The Care & Keeping of You," which has sold over three million copies. Dr. Fine has served on the Executive Committee, Bioethics Committee and the Medical Informatics Committee at Cedars-Sinai Medical Center. He is a former Clinical Instructor of Medicine at both the UCLA and USC Schools of Medicine and was chosen by Los Angeles Magazine as one of the Best Doctors in Los Angeles.
According to Lorsch, "Dr. Natterson and Dr. Fine will make a great addition to the Company's Medical Board of Advisors, helping us educate two specialty markets on the value of PHRs. Dr. Natterson's role is to strategically introduce MyMedicalRecords to the pediatric market in an effort to make both pediatricians and parents aware of the importance of having a PHR for children at a very young age. Dr. Jeremy Fine truly exemplifies what Concierge Medicine is all about and being there for his patients whenever and wherever they need him."
Over the past several years, Dr. Fine routinely deployed MyMedicalRecords accounts to his Concierge Medicine patients as part of his Concierge Medicine protocol. "As a result, Dr. Fine knows first-hand how valuable it can be in an emergency at 2 a.m. to have the ability to log in to MyMedicalRecords and access a patient's critical information regardless of where he or his patients are in the world. Consumer awareness of the importance of having a PHR is critical to the Company's business plan and there are no better professionals than Drs. Natterson and Fine to carry our message to physician colleagues, patients and parents," Lorsch added.
Working with qualified healthcare professionals, including the Company's medical advisers, MMR continues to focus on the deployment of its Personal Health Record products and services and the licensing of its patented technologies. MMRGlobal generates revenue from the sale of Personal Health Records to employers for employee benefits, direct to consumers, and patients. Through the MMR Stimulus Program, physicians and hospitals that offer MyMedicalRecords PHRs to patients can receive hundreds of thousands of dollars back from MMR as a reimbursement for the costs of maintaining medical records.
Following are brief biographies of the two new members of the Medical Board Advisors:
Dr. Jeremy Fine
Dr. Fine completed his medical training in internal medicine at Cedars-Sinai Medical Center in 2004 and was then selected to be Chief Resident. He has served on the Executive Committee, Bioethics Committee and the Medical Informatics Committee at Cedars-Sinai Medical Center. He is also a former Clinical Instructor of Medicine at both the UCLA and USC Schools of Medicine. He was chosen by Los Angeles Magazine as one of the Best Doctors in Los Angeles and has also been selected as one of California's Favorite Physicians. In 2010, he was voted Most Compassionate Doctor.
Dr. Cara Natterson
Dr. Natterson is a graduate of Harvard College and Johns Hopkins School of Medicine, trained in pediatrics at the University of California at San Francisco, and is a Board-Certified pediatrician and a Fellow of the American Academy of Pediatrics. A former partner at Tenth Street Pediatrics in Santa Monica, California, she now runs Worry Proof Consulting, the first of its kind pediatric practice that offers parents open-ended time to review everything from medical questions and biology basics to child development and parenting issues. Dr. Natterson appears on television, in print, and on the web, and is a New York Times bestselling author, having written several books on parenting and child health. Her most recent titles were published in February 2013: "The Care and Keeping of You 1: The Body Book for Younger Girls" and "The Care and Keeping of You 2: The Body Book for Older Girls." Dr. Natterson's consulting includes Fortune 500 companies seeking expert advice on child health, wellness and safety issues.
Members of the Company's Medical Board of Advisors also includes Michel Babajanian, M.D., FAC., Board-Certified Otolaryngologist and Head and Neck Surgeon; Glenn D. Braunstein, M.D., Vice President, Clinical Innovation and Director of the Thyroid Cancer Center at Cedars-Sinai Medical Center; David E. Bresler, PhD, LAc, Author, Consultant and President, Academy for Guided Imagery; Shekhar Challa, M.D., Board-Certified Gastroenterologist and Co-Founder and President, Kansas Medical Clinic; Theodore B. Goldstein, M.D., Board-Certified Orthopedic Surgeon and Co-Medical Director, Cedars-Sinai Spine Center; William H. Goodman, M.D., Pulmonary and Critical Care Physician, Academic Appointment at Dartmouth Medical School; Lawrence D. Piro, M.D., Clinician, International Expert in Hematologic Malignancies, The Angeles Clinic and Research Institute; David Charles Rish, M.D., Board-Certified Dermatologist; and Prediman K. (PK) Shah, M.D., Director, Division of Cardiology and the Oppenheimer Atherosclerosis Research Center at Cedars-Sinai Medical Center.
About MMRGlobal MMRGlobal, Inc., through its wholly-owned operating subsidiary, MyMedicalRecords, Inc., provides secure and easy-to-use online Personal Health Records ("PHRs") and electronic safe deposit box storage solutions, serving consumers, healthcare professionals, employers, insurance companies, financial institutions, retail pharmacies, and professional organizations and affinity groups. The MyMedicalRecords PHR enables individuals and families to access their medical records and other important documents, such as birth certificates, passports, insurance policies and wills, anytime from anywhere using the Internet. MyMedicalRecords is built on proprietary, patented technologies to allow documents, images and voicemail messages to be transmitted and stored in the system using a variety of methods, including fax, phone, or file upload without relying on any specific electronic medical record platform to populate a user's account. The Company's professional offering, MMRPro, is designed to give physicians' offices an easy and cost-effective solution to digitizing paper-based medical records and sharing them with patients through an integrated patient portal. Through its merger with Favrille, Inc. in January 2009, the Company acquired intellectual property biotech assets that include anti-CD20 antibodies and data and samples from its FavId(TM)/Specifid(TM) vaccine clinical trials for the treatment of B-Cell Non-Hodgkin's lymphoma. To learn more about MMRGlobal, Inc. visit www.mmrglobal.com. View demos and video tutorials of the Company's products and services at www.mmrtheater.com.
Forward-Looking Statements All statements in this press release that are not strictly historical in nature, including, without limitation, the Company's future performance, management's expectations, beliefs, intentions, estimates or projections, constitute "forward-looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. Some can be identified by the use of words (and their derivations) such as "need," "possibility," "potential," "intend," "offer," "development," "if," "negotiate," "when," "begun," "believe," "achieve," "will," "estimate," "expect," "maintain," "plan," and "continue," or the negative of these words. Actual outcomes and results of operations and the timing of selected events may differ materially from the results predicted, and any reported results should not be considered as an indication of future performance. Such statements are necessarily based on assumptions and estimates and are subject to various risks and uncertainties, including those relating to the possible invalidity of the underlying assumptions and estimates and possible changes or developments in economic, business, industry, market, legal and regulatory circumstances and conditions and actions taken or omitted to be taken by third parties, including customers, suppliers, business partners, agents, potential licensees, competitors and legislative, judicial and other governmental authorities and officials. Factors that could cause or contribute to such differences include, but are not limited to: unexpected outcomes with respect to intellectual property enforcement actions, claims of intellectual property infringement and general intellectual property litigation; our ability to maintain, develop, monetize and protect our patent portfolio for both the Company's health IT and biotechnology intellectual property assets in the U.S. and internationally; the timing of milestone payments in connection with licensing our intellectual property; our ability to establish and maintain strategic relationships; changes in our relationships with our licensees; the risk the Company's products are not adopted or viewed favorably by the healthcare community and consumer retail market; business prospects, results of operations or financial condition; risks related to the current uncertainty and instability in financial and lending markets, including global economic uncertainties; the timing and volume of sales and installations; the length of sales cycles and the installation process; the market's acceptance of new product and service introductions; programs and initiatives, including the MMR Stimulus Program; competitive product offerings and promotions; changes in government laws and regulations and future changes in tax legislation and initiatives in the healthcare industry both in the U.S. and internationally; undetected errors in our products; the possibility of interruption at our data centers; risks related to third party vendors; risks related to obtaining and integrating third-party licensed technology; risks related to a security breach by third parties; risks associated with recruitment and retention of key personnel; other litigation matters; uncertainties associated with doing business internationally across borders and territories; and additional risks discussed in the Company's filings with the Securities and Exchange Commission. The Company is providing this information as of the date of this release and, except as required by applicable law, does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise.
Michael Selsman Public Communications Co. email@example.com (310) 922-7033